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Activation of the IkB Kinase Complex by TRAF6
Requires a Dimeric Ubiquitin-Conjugating Enzyme
Complex and a Unique Polyubiquitin Chain
through covalent modification by Ub. Ubiquitination of
a protein is carried out by an enzymatic cascade com-
posed of E1 (Ub activating enzyme), E2 (Ub-conjugating
enzyme), and E3 (Ub protein ligase). Ub is first activated
by E1 in the presence of ATP to form a high energy
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thioester bond. The activated Ub is then transferred to†Department of Biochemistry and Howard Hughes
a member of the E2 family, which, in conjunction withMedical Institute
E3, conjugates Ub onto a lysine residue of the targetUniversity of Texas Southwestern Medical Center
protein to form an isopeptide bond (reviewed by Laney
Dallas, Texas 75390 and Hochstrasser, 1999). Conjugated Ub itself can be
‡Department of Biochemistry further ubiquitinated through one of its seven lysine resi-
School of Public Health dues to form a polyubiquitin (polyUb) chain. A typical
Johns Hopkins University Ub–Ub linkage within a polyUb chain recognizable by
Baltimore, Maryland 21205 the proteasome involves lysine-48 (K48) of one Ub and
the carboxyl terminus of the next Ub (Chau et al., 1989).
PolyUb chains linked through other lysines of Ub also
exist in cells, but the function of these chains is poorly
understood (reviewed by Pickart, 1997). The specificitySummary
in selecting target proteins for ubiquitination is deter-
mined to a certain extent by E2s and to a larger extentTRAF6 is a signal transducer in the NF-kB pathway
by E3s, the latter comprising a large and diverse familythat activates IkB kinase (IKK) in response to proin-
of proteins capable of binding to specific protein sub-flammatory cytokines. We have purified a heterodi-
strates. Recent studies have identified the IkB-E2 as americ protein complex that links TRAF6 to IKK activa-
member of the Ubc4/5 family, and IkB-E3 as a multipro-tion. Peptide mass fingerprinting analysis reveals that
tein complex composed of Skp1, Cul1, Roc1, and anthis complex is composed of the ubiquitin conjugating
F-box/WD40 protein called bTrCP/Slimb, which bindsenzyme Ubc13 and the Ubc-like protein Uev1A. We specifically to phosphorylated IkB (reviewed by Ma-
find that TRAF6, a RING domain protein, functions niatis, 1999).
together with Ubc13/Uev1A to catalyze the synthesis Signal-induced phosphorylation of IkBa is a prerequi-
of unique polyubiquitin chains linked through lysine- site for its ubiquitination and subsequent degradation
63 (K63) of ubiquitin. Blockade of this polyubiquitin (Chen et al., 1995). IkBa is phosphorylated at two spe-
chain synthesis, but not inhibition of the proteasome, cific serine residues (Ser32 and Ser36) following stimula-
prevents the activation of IKK by TRAF6. These results tion of cells (Brockman et al., 1995; Brown et al., 1995).
unveil a new regulatory function for ubiquitin, in which A 700 kDa protein kinase complex was first identified
IKK is activated through the assembly of K63-linked as an activity that phosphorylates IkBa at the signaling
serine residues (Chen et al., 1996). Surprisingly, the ac-polyubiquitin chains.
tivity of this kinase complex can be induced by ubiquiti-
nation, a novel phenomenon suggestive of a regulatoryIntroduction
role of Ub. Subsequently, this IkB kinase complex was
found to be activated independently by phosphorylationNF-kB provides a paradigm for a transcription factor
through MEKK1, a kinase of the JNK/SAPK pathwaythat is regulated primarily via nuclear translocation (Sen
(Lee et al., 1997). Recent studies have led to the identifi-and Baltimore, 1986; Baeuerle and Baltimore, 1988). In
cation of two catalytic subunits of the IkB kinase com-unstimulated cells, NF-kB is sequestered in the cyto-
plex as IKKa and IKKb, and a regulatory subunit asplasm through association with an inhibitory protein of
NEMO/IKKg (reviewed by Israel, 2000). Genetic studiesthe IkB family. Upon stimulation of cells by various ago-
demonstrate that NEMO and IKKb are essential for NF-nists, such as tumor necrosis factor a (TNFa) and in-
kB activation, whereas removal of IKKa does not signifi-terleukin 1b (IL-1b), IkB proteins are rapidly phosphory-
cantly impair the NF-kB pathway. The mechanism bylated by an IkB kinase (IKK) complex and then degraded
which NEMO regulates IKK activity is presently un-by the ubiquitin (Ub)-proteasome pathway (reviewed by
known.Ghosh et al., 1998). Following IkB degradation, NF-kB
The identification of the IKK complex opens the doortranslocates into the nucleus where it regulates the ex-
to exploring the important question of how IKK inte-pression of a wide spectrum of genes involved in immu-
grates multiple signals from diverse pathways. While
nity, inflammation, apoptosis, and other cellular pro- there are many different agents that can activate NF-
cesses.
kB through the IKK complex, the best characterized
The importance of IkB degradation in the NF-kB path- signaling cascades are those emanating from the cyto-
way is underlined by the observation that blockade of kines TNFa and IL-1b. For example, binding of IL-1b to
IkB degradation prevents activation of NF-kB by most, its receptor (IL-1R) leads to the formation of a complex
if not all, stimuli (reviewed by Chen and Maniatis, 1998). between IL-1R and the receptor accessory protein (IL-
IkB is targeted to degradation by the proteasome 1RAcP), which in turn triggers the assembly of a sub-
membraneous signaling complex containing an adaptor
MyD88, a protein kinase IRAK, and a RING finger domain§ To whom correspondence should be addressed (e-mail: jchen@
hamon.swmed.edu). protein TRAF6 (Cao et al., 1996). How TRAF6 and other
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TRAF proteins transduce signals to the IKK complex is
not understood. Although MEKK1 and NIK, a kinase
of the MEKK family (Malinin et al., 1997), have been
postulated to link TRAF proteins to IKK activation, recent
genetic studies found that deletion of MEKK1 or NIK
did not impair IKK or NF-kB activation (Shinkura et al.,
1999; Xia et al., 2000). In contrast, genetic ablation of
TRAF6 completely abolishes IKK activation in response
to IL-1b and several other physiologic ligands, including
CD40 and LPS (Lomaga et al., 1999; Naito et al., 1999).
Thus, there is a significant gap in the pathway between
TRAF6 and the IKK complex.
We undertook a biochemical approach to filling in the
gap between TRAF6 and IKK. Our approach begins with
the establishment of a cell-free system that activates
IKK in a NEMO- and TRAF6-dependent manner. Bio-
chemical fractionation of the cell extract reveals two
distinct factors that are required to activate IKK by
TRAF6. We now report the purification and characteriza-
tion of one of these factors, which turns out to be a
dimeric ubiquitin-conjugating enzyme (E2) complex
composed of Ubc13 and Uev1A (Mms2). This E2 com-
plex was previously shown to catalyze the assembly of
Figure 1. A Cell-Free System that Activates IKK in Response tounique polyUb chains linked through lysine-63 (K63) of
TRAF6 and NEMOUb (Hofmann and Pickart, 1999). We find that recombi-
(A) Phosphorylation of endogenous IkBa in crude cell extracts. Pro-nant Ubc13/Uev1A supports the activation of IKK by
tein extracts (4.5 mg/ml) from 70Z (wild type, lanes 1–3) or 1.3 E2TRAF6, whereas depletion of Uev1A abolishes TRAF6-
(NEMO-deficient, lanes 4–6) pre-B cells were incubated with recom-
mediated activation of IKK. TRAF6 facilitates the assem- binant TRAF6 (0.1 mM, lanes 2, 3, 5, and 6) and NEMO (50 nM, lanes
bly of K63-linked polyUb chains by Ubc13/Uev1A, and 3 and 6) or with ATP (2 mM) alone (lanes 1 and 4) at 308C for 1
this activity requires the RING finger domain of TRAF6. hr. Phosphorylated IkBa was detected by immunoblotting with a
Furthermore, Ub mutants that fail to assemble into K63- phospho-IkBa-specific antibody.
linked chains prevent activation of IKK by TRAF6 and (B) Specificity of IkBa phosphorylation. In vitro translated,
35S-labeled IkBa (lanes 1–2) or IkBa serine mutants (lanes 3–8) wereUbc13/Uev1A, whereas inhibition of proteasome does
used as the substrate in the reaction that contains protein extractsnot affect IKK activation. These results indicate that
from 293 cells (5 mg/ml) and TRAF6 (0.1 mM). After incubation at 308CTRAF6 functions as a Ub ligase (E3), which, together
for 1 hr, the reaction products were analyzed by a PhosphorImagerwith the E2 Ubc13/Uev1A, mediates the assembly of
following SDS-PAGE. WT: wild type; S32A or S36A, serine 32 or 36K63-linked polyUb chains required for IKK activation.
was substituted by alanine; S32/36A: both serines 32 and 36 were
Our results also unveil a novel nonproteolytic function changed to alanine; p-IkBa: phosphorylated IkBa.
for Ub, which in this case positively regulates a protein
kinase activity.
NF-kB agonists trigger the phosphorylation of IkBaResults
at both serines 32 and 36. To determine whether IkBa
is phosphorylated at these serine residues in the in vitroA Cell-Free System that Activates IKK
TRAF6-inducible system, we tested in vitro translated,in Response to TRAF6
35S-labeled IkBa serine mutants in our assay. While wild-Overexpression of TRAF6 in cells activates NF-kB through
type IkBa was fully phosphorylated, as indicated by thethe IKK complex (Cao et al., 1996; Regnier et al., 1997).
electrophoretic mobility shift (lane 2), mutation at bothWe sought to recapitulate the TRAF6-dependent activa-
serines 32 and 36 abolished this phosphorylation (lanetion of IKK in vitro in order to identify the missing link
8). Single point mutation at either S32 or S36 led to anbetween TRAF6 and IKK through biochemical fraction-
intermediary gel shift (lanes 4 and 6), which is indicativeation. As shown in Figure 1A, addition of recombinant
of single site phosphorylation at the remaining wild-typeTRAF6 to cell extracts prepared from 70Z pre-B cells
serine residue. Therefore, the in vitro TRAF6-inducibleled to the phosphorylation of endogenous IkBa that
system retains the specificity of IkBa phosphorylation.could be detected with a phospho-IkBa-specific anti-
body (lane 2). This reaction is strictly dependent on NEMO,
since cell extracts prepared from 1.3E2, a NEMO-defi-
TRAF6-Dependent Activation of IKK Requirescient line derived from 70Z cells (Courtois et al., 1997),
Intermediary Factorsfailed to phosphorylate IkBa in the presence of TRAF6
To determine whether TRAF6 activates IKK directly, we(lane 5). Moreover, addition of recombinant NEMO to
purified the IKK complex from unstimulated HeLa cellsthe 1.3E2 extract restored IkBa phosphorylation in re-
or from calf thymus through several chromatographicsponse to TRAF6 (lane 6). Genetic experiments have
steps, including an ATP-affinity column step. The puri-previously demonstrated that NEMO is essential for IKK
fied IKK complex from HeLa cells contains IKKa, IKKb,activation by most stimuli, including components of the
and NEMO (data not shown) and can be activated di-TRAF6 pathway (Yamaoka et al., 1998; Rudolph et al.,
rectly by MEKK1 (Figure 2A, lane 5) (Lee et al., 1998).2000). Thus, the in vitro TRAF6-inducible system de-
The ability to purify this latent IKK complex from HeLascribed here mimics the stringent requirement of NEMO
for IKK activation. cells allows us to search for upstream factors required
Ubiquitin-Dependent Activation of IKK by TRAF6
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shown in Figure 3C. This factor has an apparent molecu-
lar size of 35 kDa based on gel filtration chromatography
(data not shown), and is separated into two bands on
SDS-PAGE with molecular sizes of 16 and 19 kDa, re-
spectively (Figure 3B). The intensity of these bands cor-
related with IKK-stimulatory activity, indicating that they
are candidate subunits of TRIKA1 (a and b subunits).
The 16 and 19 kDa bands were excised for mass
spectrometric analysis following digestion with trypsin.
Peptide mass fingerprinting (MALDI-TOF) of the 16 kDa
protein identified 9 peptides whose masses matched
those predicted from human Ubc13, a Ub-conjugating
enzyme (Figure 3D). The 19 kDa protein has 11 peptides
whose masses matched those of an isoform of human
Uev1 such as Uev1A (Figure 3E), a Ub-conjugating E2
enzyme variant (UEV) that is structurally related to E2
enzymes but lacks the catalytic cysteine residue found
in a typical E2 (Rothofsky and Lin, 1997; Sancho et al.,
1998).
Recombinant Ubc13/Uev1A Complex Supports
the Activation of IKK by TRAF6
To verify that Ubc13 and Uev1A are indeed components
of TRIKA1, we expressed these proteins in E. coli andFigure 2. Activation of IKK by TRAF6 Requires Intermediary Factors
purified the recombinant proteins to apparent homoge-(A) TRAF6 does not activate IKK directly. 293 cell extracts or purified
neity with the aid of a hexahistidine (His6) affinity tag.IKK complex (5 nM) was incubated with 35S-IkBa in the presence of
ATP (all lanes) and TRAF6 (0.1 mM, lanes 2 and 4). As a control, Recombinant Ubc13 and Uev1A form a heterodimer that
MEKK1 (0.1 mM) was used to activate the IKK complex directly migrates at z45 kDa on a gel filtration column (data
(lane 5). not shown). In the presence of TRAF6, the recombinant
(B) Activation of IKK by TRAF6 requires two distinct factors. HeLa Ubc13 and Uev1A activated IKK in a manner that corre-
cytosolic extract (S100) was fractionated on Q-Sepharose. Fr.I is lated with the formation of the heterodimer (Figure 4A).the flow through from the column (referred to as TRIKA1), whereas
Furthermore, mutation of the active site Cys-87 of Ubc13Fr.IIa contains bound proteins eluted with 0.2 M NaCl (referred to
(C87A) abolished its ability to support IKK activation byas TRIKA2). Each fraction alone (lanes 4 and 5) or in combination
TRAF6 (Figure 4B). Like the native TRIKA1, recombinant(lanes 3) was added into a reaction mixture that contains the purified
Ubc13/Uev1A stimulated IkBa phosphorylation by IKKIKK complex, 35S-IkBa, TRAF6, and ATP as described in (A). In lanes
1 and 2, IKK complex or TRAF6 was omitted from the reaction, at both serines 32 and 36 (Figure 4C). We also tested
respectively. whether other E2s could support TRAF6-mediated IKK
activation (Figure 4D). Among several E2s tested, only
Ubc13/Uev1A was capable of activating IKK together
with TRAF6. These results confirm that Ubc13/Uev1A isfor its activation. One of the candidate upstream activa-
the TRIKA1 that links TRAF6 to IKK activation.tors is TRAF6. However, unlike MEKK1, TRAF6 did not
activate the purified IKK complex directly (Figure 2A,
lanes 4 and 5). In contrast, the crude extract from 293 Ubc13/Uev1A Is Required for IKK Activation
cells can be activated by TRAF6 (lane 2), suggesting by TRAF6
the existence of intermediary factors required for IKK The tight binding between Ubc13 and Uev1A makes it
activation by TRAF6 in the extract. As an initial step to feasible to deplete endogenous Uev1A from crude cell
identify these factors, we fractionated HeLa cytosolic extracts with immobilized GST-Ubc13, thus providing
extract (S100) on Q-Sepharose through step elution with an opportunity to address the consequence of removing
increasing concentration of NaCl (Figure 2B). Signifi- Uev1A. This is particularly useful in light of the fact that
cantly, the activation of the IKK complex by TRAF6 re- the antibodies generated against Ubc13 or Uev1A fail
quires at least two fractions, the unbound fraction (Fr.I) to immunoprecipitate the respective proteins, although
and the 0.1–0.2 M NaCl eluate (Fr.IIa, lane 3). Omission they can detect the proteins by immunoblotting (data
of either fraction abolishes IKK activation by TRAF6 not shown). As shown in Figure 5A, cell extracts were
(lanes 4 and 5). The factor present in Fr.I is hereby re- devoid of Uev1A after passage through GST-Ubc13-
ferred to as TRAF6-Regulated IKK Activator 1 (TRIKA1), Sepharose (lane 2), whereas GST-Sepharose did not
whereas the factor present in Fr.IIa is referred to as retain any Uev1A from the extracts (lanes 3 and 5). Con-
TRIKA2. sequently, cell extracts depleted of Uev1A are severely
defective in IKK activation in the presence of TRAF6
(Figure 5B, lane 7), whereas control extracts retain fullPurification and Identification of TRAF6-Regulated
IKK Activator 1 (TRIKA1) IKK activation potential (lanes 3 and 10). Addition of
recombinant Ubc13/Uev1A to the Uev1A-depleted ex-We have purified TRIKA1 from HeLa cytosolic extracts to
apparent homogeneity through six steps of conventional tracts restored IKK activation in response to TRAF6 (lane
8). These results indicate that Ubc13/Uev1A is requiredchromatography (Figure 3A). Silver staining of fractions
from the last MonoQ step is shown in Figure 3B, and for IKK activation by TRAF6 in vitro.
To determine whether Ubc13/Uev1A is required forthe IKK stimulatory activity assay of the same fractions
Cell
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Figure 3. Purification and Identification of
TRIKA1
(A) Purification scheme.
(B) Silver staining of fractions from the
MonoQ column (last step). Aliquots (8 ml) of
the indicated fractions were subjected to
SDS-PAGE (13%) followed by silver staining.
(C) TRIKA1-dependent IKK activation assay.
0.5 ml of the indicated MonoQ fractions was
used in the IKK activation assay as described
in Experimental Procedures.
(D) Amino acid sequence of human Ubc13.
(E) Amino acid sequence of human Uev1A.
Underlined are the peptides whose masses
match those of TRIKA1a and TRIKA1b, re-
spectively.
NF-kB activation in living cells, we transfected an ex- TRAF6 Facilitates the Assembly of K63-Linked
polyUb Chains in Conjunctionpression construct encoding the Ubc13(C87A) mutant
into 293 cells together with a reporter gene that ex- with Ubc13/Uev1A
Previous studies have shown that Ubc13 and Mms2, apresses luciferase under the control of three tandem
repeats of NF-kB binding sites (Figure 5C). The trans- yeast homolog of Uev1A, form an E2 complex to catalyze
the synthesis of unique polyUb chains linked throughfected cells were stimulated with IL-1b, TNFa, or by
cotransfection with expression constructs encoding lysine-63 (K63) of ubiquitin (Hofmann and Pickart, 1999).
This finding, together with our present results that thisTRAF6, TRAF2, NIK, or the TAX protein of the human T
cell leukemia virus (HTLV1). As a control, the expression E2 complex is involved in IKK activation by TRAF6,
raises the possibility that TRAF6 may also be involvedof a luciferase reporter gene driven by Gal4 was also
examined, using hybrid transcription activators com- in ubiquitination. In fact, TRAF6 contains a RING finger
domain and five repeats of zinc fingers at its N terminusposed of the DNA binding domain of Gal4 and the trans-
activation domain of c-Rel (Gal4-Rel) or VP16 (Gal4- (Cao et al., 1996). Several other RING finger proteins
have previously been shown to function as ubiquitinVP16). Remarkably, overexpression of Ubc13(C87A) led
to potent inhibition of NF-kB activation by IL-1b, TNFa, ligases in polyubiquitination (Lorick et al., 1999). To test
whether TRAF6 has a role in ubiquitination, we carriedTRAF6, or TRAF2. In contrast, Ubc13(C87A) had little
effect on NF-kB activation by NIK or TAX, or on Gal4- out an in vitro ubiquitination assay in the presence of
E1, Ubc13/Uev1A (as an E2), ATP, and Ub (Figure 6A).dependent transcription by Rel or VP16. Thus, Ubc13/
Uev1A appears to be involved primarily in the pathways When all components were present, polyUb chain syn-
thesis was readily detectable with a Ub-specific anti-that require TRAF proteins (TRAF2 for TNFa, and TRAF6
for IL-1b). Taken together, these results strongly suggest body (lane 5). In the absence of any of the components,
no significant polyubiquitination was observed (lanes 1,that Ubc13/Uev1A is required for NF-kB activation by
TRAF proteins in the IL-1 and TNF pathways. 2, 3, and 4). (The Ub2 seen in lanes 1–5 is principally a
Ubiquitin-Dependent Activation of IKK by TRAF6
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Figure 5. TRIKA1 Is Required for IKK Activation by TRAF6
(A) Depletion of Uev1A by GST-Ubc13-Sepharose. Protein extract
of 293 cells was incubated with GST-Ubc13-Sepharose (lanes 2 and
4) to remove endogenous Uev1A from the extracts (see Experimental
Procedures). As a control, the extract was also treated with GST-
Sepharose (lanes 3 and 5). Aliquots of the supernatants (unbound;
lanes 2 and 3) and Sepharose beads (bound; lanes 4 and 5) were
analyzed by immunoblotting with an antibody against Uev1A. As a
control, 20 mg of the 293 cell extracts was also probed for Uev1A
(lane 1).
(B) TRAF6 failed to activate IKK in Uev1A-depleted extracts. 293
cell extracts treated as described in (A) were tested for IKK activation
in the presence of TRAF6 (lanes 3, 7, and 10), recombinant Ubc13/
Uev1A (lanes 2 and 6), or both (lanes 4, 8, and 11).
(C) Interference of Ubc13/Uev1A inhibits NF-kB activation in cells.
The expression construct encoding Ubc13(C87A) was cotransfected
into 293 cells together with a luciferase reporter gene (kB3-Luc or
Gal4-luc). NF-kB was induced by stimulation with IL-1b (20 ng/ml)
Figure 4. Reconstitution of TRAF6-Dependent IKK Activation with or TNFa (20 ng/ml) for 6 hr, or by cotransfection with expression
Recombinant TRIKA1(Ubc13/Uev1A) constructs encoding TRAF6 (300 ng DNA), TRAF2 (200 ng), NIK (10
ng), HTLV1 TAX (20 ng), Gal4-Rel (300 ng) or Gal4-VP16 (100 ng).(A) Ubc13 and Uev1A forms a heterodimeric complex. His6-Ubc13
The luciferase activity was measured 48 hr after transfection. Theand His6-Uev1A were expressed in E. coli and affinity purified. 1.2
result shown was an average of duplicated experiments.mg of His6-Ubc13 was mixed with 1 mg of His6-Uev1A and then
loaded onto a Superdex-75 column. Aliquots (2 ml) of the indicated
fractions from the column were subjected to SDS-PAGE (13%) fol-
contaminant in the commercial Ub). Inclusion of a Ublowed by Coomassie blue staining (upper panel). 0.5 ml of the same
fractions (diluted 1/10) was assayed for stimulation of IKK in the mutant (KO) in which all seven lysines were mutated to
presence of TRAF6 (lower panel). arginine prevented polyUb chain formation (lanes 6–8).
(B) Point mutation at Cys-87 of Ubc13 abolishes its ability to support Restoration of a lysine at position 48 (K48) on an other-
TRAF6-mediated IKK activation. TRIKA1 was assembled in vitro by wise lysine-less background was not sufficient to re-
mixing His6-Uev1A with equal amounts of His6-Ubc13 or His6-Ubc13 store polyubiquitination (lane 9). In contrast, restoration
(C87A). The wild-type (lanes 3 and 4) or mutant (lanes 5 and 6)
complex (0.4 mM) was added to the IKK activation assay in the
presence (lanes 2, 4, and 6) or absence (lanes 1, 3, and 5) of TRAF6.
As a control, native TRIKA1 purified from HeLa cells (MonoQ fraction Ubc13/Uev1A (0.4 mM); and lanes 9–12 contain no TRIKA1. SS: wild-
23, Figure 3B) was also tested in the assay (lanes 1 and 2). type IkBa; AS: S32A; SA: S36A; AA: S32A/S36A.
(C) Specificity of IkBa phosphorylation in the reconstituted system. (D) TRIKA1 (Ubc13/Uev1A) is a specific E2 that activates IKK in
In vitro translated 35S-IkBa and the serine mutants were tested as conjunction with TRAF6. Different E2s (20 mg/ml) as indicated were
substrates for IKK in the reconstituted system. Lanes 1–4 contain tested for their ability to activate IKK in the presence of TRAF6.
native TRIKA1 (MonoQ Fr.23, 0.5 ml); lanes 5–8 contain recombinant Each E2 was active in forming thioester with Ub (data not shown).
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of a lysine at position 63 (K63) restored polyubiquitina-
tion (lane 10). These results show that TRAF6 facilitates
the synthesis of polyUb chains through K63 rather than
K48. In this regard, TRAF6 is a Ub ligase (E3) that part-
ners with Ubc13/Uev1A (E2). We also found that TRAF2
functioned together with Ubc13/Uev1A to catalyze the
synthesis of K63-linked polyUb chains (data not shown),
consistent with the obligatory role of Ubc13/Uev1A in
NF-kB activation by TNFa and TRAF2 (Figure 5C).
To determine whether the RING finger domain of
TRAF6 is important for its Ub-conjugating activity, we
mutated the highly conserved cysteine and histidine res-
idues in the RING domain to generate two point mutants,
C70A and C85A/H87A. These constructs were expressed
in 293 cells as Flag-tagged proteins and immunopurified
for ubiquitination assays (Figure 6B). While wild-type
TRAF6 catalyzed the assembly of K63-linked polyUb
chains from a K63 Ub mutant in the presence of E1
and Ubc13/Uev1A (lane 4), the RING finger mutations
abolished this Ub-conjugating activity (lanes 6 and 8).
These same mutations also abolished the ability of
TRAF6 to activate the expression of an NF-kB reporter
gene (luciferase) when overexpressed (Figure 6C), sug-
gesting that the NF-kB-inducing activity of TRAF6 is
linked to its Ub-conjugating activity through the use of
the RING domain.
K63-Linked polyUb Chains Are Involved in IKK
Activation by TRAF6
Our findings that TRAF6 and Ubc13/Uev1A are involved
in IKK activation, and that they catalyze the synthesis
of K63-linked polyUb chains, led us to investigate the
role of these unique Ub chains in IKK activation. We
first examined a panel of Ub mutants for their ability to
activate IKK in vitro (Figures 7A and 7B). These mutants
include a lysine-less mutant (Figure 7B, lane 2, KO),
single-lysine mutants, which contain one lysine with the
remaining six lysine residues mutated to arginine (K6,
K11, K27, K29, K33, K48, and K63; lanes 3–9), and single
K/R mutants, which contain a single point mutation from
lysine to arginine with the remaining lysines intact (R11,
R29, R48, and R63; lanes 10–13). In addition, we also
tested methylated Ub (MeUb, lane 1), in which all seven
lysine residues were blocked by methylation, thus pre-
venting elongation of Ub chains. Strikingly, MeUb, KO,
and all single-lysine mutants except for K63 fail to sup-
port IKK activation by TRAF6 (lanes 1–9), indicating that
K63 is the only important lysine on Ub required for this
Figure 6. TRAF6 Facilitates the Assembly of K63-Linked polyUb function. In further support of this conclusion, a single
Chains in Conjunction with Ubc13/Uev1A point mutation at position 63 from Lys to Arg (R63) abol-
(A) Synthesis of polyUb chains by TRAF6. The ubiquitination reaction ished the stimulatory activity of Ub (lane 13), whereas
contains E1, E2 (TRIKA1), TRAF6, Ub, and ATP as indicated. PolyUb mutations at other lysines had no effect (lanes 10–12).
chains were detected by immunoblotting with a Ub-specific anti- These results strongly suggest that K63-linked polyUb
body. The band marked as Ub2 is diubiquitin that copurifies with chains play an important role in TRAF6-mediated IKK
Ub and is present in the Ub purchased from Sigma. KO (lanes 6–8): activation.
a lysine-less Ub mutant; K48 (lane 9) and K63 (lane 10): all lysines
To determine whether the assembly of K63-linkedon Ub are mutated to arginine except for K48 or K63.
polyUb chains is required for IKK activation by TRAF6(B) Synthesis of K63-linked polyUb chains by TRAF6 requires an
in crude cell extracts, we tested several Ub lysine mu-intact RING finger. Wild-type (WT) and the RING finger mutants
tants for their ability to interfere with IKK activation in(C70A and C85AH87A) of TRAF6 were expressed in 293 cells and
immunopurified using an anti-FLAG antibody. The purified TRAF6 the extracts (Figure 7C). Addition of wild-type or K63 Ub
proteins were added into a Ubiquitination reaction containing E1,
myc-K63-Ub and ATP in the presence (lanes 2, 4, 6, and 8) or ab-
(C) An intact RING finger is required for NF-kB activation by TRAF6.sence (lanes 1, 3, 5, and 7) of Ubc13/Uev1A. Half of the reaction
mixture was processed by immunoblotting with a myc-specific anti- Expression plasmids encoding TRAF6 and mutants were trans-
fected into 293 cells together with the reporter kB3-Luc. Forty-eightbody (upper panel), and the other half probed with an anti-FLAG
antibody. No ubiquitination of TRAF6 itself was detected. The band hours after transfection, cells were harvested for luciferase activity
assays.marked by an asterisk is likely to be ubiquitinated E1 itself.
Ubiquitin-Dependent Activation of IKK by TRAF6
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results further strengthen the conclusion that TRAF6-
mediated activation of IKK requires the assembly of
K63-linked polyUb chains.
The critical role of K63 rather than K48 of Ub in IKK
activation raises the question of whether proteasomal
degradation plays any role at all in IKK activation, since
K48-linked polyUb chains are preferentially recognized
by the proteasome (Chau et al., 1989). In our in vitro
reconstitution system, no proteasome was added to the
assay, suggesting that IKK activation does not require
proteasome. To rule out the possibility that any residual
proteasomal activity might be required for IKK activa-
tion, we added proteasome inhibitors MG132 (Figure
7D, lanes 4–6) or lactacystin (lanes 7–9) to the assay.
No inhibition of IKK activation was observed in the pres-
ence of MG132 or lactacystin at 20 mM, a concentration
known to completely block proteasomal activity (Chen
et al., 1995). As a control, the kinase inhibitor stauro-
sporin (STS) significantly inhibited IKK activity in the
extract (lane 11). This experiment, together with previ-
ous results that proteasome inhibitors do not interfere
with IkB phosphorylation in vivo (Palombella et al., 1994),
shows that IKK is activated by TRAF6 through a mecha-
nism involving K63-linked polyUb chains, but not protea-
somal degradation.
Discussion
In this report, we describe the purification and identifica-
tion of a protein complex that links IKK to its upstream
activator TRAF6. This complex is composed of Ubc13
and Uev1A (Mms2), a dimeric Ub-conjugating enzyme
previously shown to catalyze the synthesis of K63-linked
polyUb chains (Hofmann and Pickart, 1999). Several
Figure 7. K63-Linked polyUb Chains Mediate the Activation of IKK
lines of evidence suggest that Ubc13/Uev1A is indeedin Response to TRAF6
a critical factor that mediates IKK activation by TRAF6.
(A) Illustration of Ub lysine mutants.
First, recombinant Ubc13/Uev1A dimer supports IKK(B) K63 of Ub is necessary and sufficient to activate IKK. Wild-type
activation in a reconstituted system; second, mutationor mutant Ub (0.1 mM) was included in the IKK activation assay
of the catalytic cysteine of Ubc13 abolishes its abilityusing 35S-IkBa as the substrate. KO (lane 2): lysine-less Ub; K6-K63
to activate IKK; third, among several known E2s tested,(lanes 3–9): single lysine Ub at the indicated position; the other six
lysine residues were substituted by arginine; R11, R29, R48, and Ubc13/Uev1A is uniquely capable of activating IKK in
R63 (lanes 10–13): single point mutation (K to R) at the indicated vitro, consistent with the purification data showing that
position; the remaining lysine residues were wild type. only a single peak of TRIKA1 activity was detected
(C) Ub mutants defective in K63-linked polyUb chain synthesis ex- throughout the fractionation steps; fourth, removal of
erts dominant-negative effects on IKK activation in crude cell ex- Uev1A renders cell extracts defective in activating IKK
tracts. Wild-type or mutant Ub (0.1 mM) was added to 70Z cell
in response to TRAF6; and finally, interference of Ubc13/extracts together with TRAF6 (upper panel), MEKK1 (middle panel),
Uev1A in cells blocks NF-kB activation by IL-1b andor IKKb (lower panel). After addition of ATP, the mixture was incu-
TNFa, two agonists known to transduce signals throughbated at 308C for 1 hr before immunoblotting with an IkBa-specific
TRAF proteins.antibody.
(D) Proteasomal activity is not required for the activation of IKK by Consistent with a previous report (Chen et al., 1996),
TRAF6. Protein extracts from 70Z cells were incubated with MG132 we have found that another Ub-conjugating enzyme of
(lanes 4–6, 20 mM), lactacystin (lanes 7–9, 20 mM), staurosporin (STS, the Ubc4/5 subfamily can also activate a partially puri-
lanes 10–11, 1 mM), or 10% DMSO (solvent for the compounds, fied IkB kinase fraction. Immunodepletion of IKK from
lanes 1–3) in the presence of TRAF6 (lanes 2, 5, 8, and 11) or MEKK1 the partially purified fraction abolishes the Ub-depen-
(lanes 3, 6, and 9). After preincubation on ice for 15 min, the reactions
dent phosphorylation of IkBa (C. W. and Z. J. C., unpub-were initiated by addition of ATP and proceeded at 308C for 1 hr.
lished data), indicating that IKK is the kinase that isPhosphorylation of IkBa was analyzed by immunoblotting with an
activated by ubiquitination. However, highly purified IKKIkBa antibody.
complex can no longer be activated directly by Ubc4/5,
although it can be activated directly by MEKK1 (data
not shown). Significantly, when the purified IKK complexhad no effect on endogenous IkBa phosphorylation
stimulated by TRAF6 (lanes 3 and 6). In contrast, Ub was supplemented with a fraction that is depleted of
IKK, Ubc4/5-dependent activation of IKK was restored,mutants lacking any lysine (KO) or retaining only one
lysine at position 48 (K48) exert a dominant-negative suggesting the existence of a factor required for IKK
activation by Ubc4/5 (C. W. and Z. J. C., unpublishedeffect on endogenous IKK activation by TRAF6 (lanes 4
and 5). These mutants did not interfere with IKK activa- data). This factor, which remains to be characterized,
does not support the activation of IKK by Ubc13/Uev1Ation triggered by MEKK1 or IKKb. Taken together, these
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and TRAF6. Conversely, Ubc4/5 cannot substitute for The mechanism by which p62 activates IKK in these
pathways is not clear, but is thought to involve the bind-Ubc13/Uev1A in the activation of IKK by TRAF6 (Figure
4D). Unlike TRAF6, whose essential role in the NF-kB ing of p62 to RIP and TRAF6, respectively. Intriguingly,
independent studies have found that p62 is a polyUbpathway is well established, it is presently unknown how
Ubc4/5 is connected to the known NF-kB pathways. chain binding protein (Vadlamudi et al., 1996). Further
studies are needed to determine whether the Ub bindingThe involvement of Ubc13/Uev1A as a Ub-conjugating
enzyme in TRAF6-mediated IKK activation led us to in- property of p62 is relevant to its stimulatory function in
the NF-kB pathway.vestigate the potential role of TRAF6 in ubiquitination.
Indeed, TRAF6 greatly facilitates the synthesis of K63- How does ubiquitination lead to IKK activation? Two
possible scenarios come to mind. In the first scenario,linked polyUb chains by Ubc13/Uev1A. This E3 activity
of TRAF6 requires an intact RING domain, a structural covalent modification of a target protein by K63-polyUb
chains could activate (in the case of an activator) ormotif that is also critical for TRAF6 to induce NF-kB in
cells. Several RING finger proteins have recently been inactivate (in the case of an inhibitor) such a protein,
just as phosphorylation can regulate the function ofshown to possess Ub-conjugating activity in conjunc-
tion with other E2s (Lorick et al., 1999). However, the a target protein. In the second scenario, K63-linked
polyUb chains could function as a tag to recruit otherrole of these RING finger proteins appears to be linked
to targeting proteins for degradation. TRAF6, on the proteins in the IKK pathway, just as phosphotyrosine
is used extensively to recruit SH2-domain-containingother hand, functions together with Ubc13/Uev1A to
mediate the synthesis of K63-linked polyUb chains. proteins in various signaling cascades. The latter possi-
bility is consistent with our preliminary results showingRad5, a RING-containing helicase, may function simi-
larly in the yeast DNA repair pathway (Ulrich and that IKK activation in vitro can be inhibited by free Ub
tetramers linked through K63 [(K63)4], but not by (K48)4Jentsch, 2000). K63 chains have been previously impli-
cated in stress response and DNA repair in yeast (data not shown). Presumably free (K63)4 chains, which
cannot be conjugated to target substrates due to the(Spence et al., 1995; Hofmann and Pickart, 1999). Inter-
estingly, conditions such as UV and DNA damaging blockade of the C terminus, function in a dominant-
negative manner by sequestering proteins that normallyagents that trigger stress response and DNA repair also
lead to IKK activation. bind to polyubiquitinated targets. While the exact mech-
anism by which K63-linked polyubiquitination activatesWe propose that K63-linked polyUb chains play an
important regulatory role in IKK activation, based on the IKK requires further investigation, our results clearly
show that proteasomal degradation is not required tofollowing lines of evidence. First, a single point mutation
at K63, but not at other lysine residues, abolishes the activate IKK. This does not mean that the target proteins
conjugated by K63 chains are not ultimately degraded,ability of Ub to support IKK activation by TRAF6; second,
restoration of a single lysine at position 63, but not at but it does mean that degradation, even if it occurs, is
not necessary for IKK activation. These results reaffirmany other position, is sufficient to activate IKK in a recon-
stituted system; third, Ub mutants that fail to assemble the notion that ubiquitination, but not degradation, plays
a regulatory role in IKK activation (Chen et al., 1996).into K63-linked polyUb chains exert dominant negative
effects on IKK activation in cell extracts; fourth, inhibi- Protein kinases are known to have complex modes
of regulation. Besides the well characterized phosphory-tion of the proteasome has no effect on IKK activation.
These results, together with the aforementioned findings lation cascades that can positively or negatively regulate
protein kinases, some kinases can also be regulated bythat IKK activation requires the catalytic cysteine of
Ubc13 and the RING domain of TRAF6, provide strong DNA, RNA, lipids, small molecules (i.e., Ca21 and cAMP),
or by protein–protein interaction (i.e., activation of cyclin-support for a critical role of K63-linked polyUb chains
in IKK activation. dependent kinases by cyclins). Our results uncover an-
other mode of kinase regulation by ubiquitination. ThisAlthough TRAF6 facilitates the assembly of free K63
chains in conjunction with Ubc13/Uev1A, free K63 mode of enzymatic regulation by Ub is unprecedented.
Mono-ubiquitination, on the other hand, could serve reg-chains do not activate IKK (see below). Thus, the K63-
linked chains that function in IKK activation are evidently ulatory function by targeting certain receptors for inter-
nalization and subsequent lysosomal, rather than pro-linked to a target protein that remains to be identified.
Further purification and characterization of TRIKA2 may teasomal, degradation (reviewed by Hicke, 1999).
Now that we show the IKK complex could be indepen-lead to the identification of such a target. We have not
detected ubiquitination of components of the IKK com- dently activated by phosphorylation or by ubiquitination
in vitro, which of these mechanisms might be responsi-plex including NEMO, IKKa, and IKKb. However, some
proteins known to participate in the NF-kB pathway have ble for IKK activation in vivo? Strong support for IKK
being activated by phosphorylation comes from the ob-been reported to undergo ubiquitination following en-
gagement of ligands. For example, stimulation of cells servation that both IKKa and IKKb contain canonical
MAPK phosphorylation sites, and that mutation of thesewith TNFa led to “some kind of covalent modification”
of the protein kinase RIP that resembles ubiquitination sites significantly interferes with IKK activation in re-
sponse to various stimuli (Mercurio et al., 1997). This(Zhang et al., 2000). The conjugated form of RIP appears
within one minute of TNFa treatment, and then decays and other experiments led to the idea that there is an
upstream kinase (IKKK) that phosphorylates IKK and iswith kinetics that coincides with transient activation of
IKK. Interestingly, there is no apparent degradation of responsible for its activation. In fact, the in vitro TRAF6-
inducible system we set up was initially designed toRIP throughout the time course when IkBa is rapidly
degraded. It remains to be determined whether this form identify a putative IKKK downstream of TRAF6. How-
ever, upon fractionation, it became clear that the factorsof RIP modification is related to IKK activation. Recently,
a protein associated with atypical PKCs called p62 has mediating IKK activation in response to TRAF6 were
ubiquitination enzymes. We had also attempted to iden-been shown to be involved in IKK activation in both the
TNF and IL-1 signaling pathways (Sanz et al., 2000). tify an IKKK through fractionation of TNFa-stimulated
Ubiquitin-Dependent Activation of IKK by TRAF6
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from human placenta cDNA library by Polymerase Chain Reactioncell extracts. However, we found that the only fraction
(PCR), and then subcloned into pFast-Bac for expression in Sf9capable of activating IKK (isolated from unstimulated
cells. All constructs were verified by automatic DNA sequencing.cells) is the activated IKK itself (from TNFa-stimulated
His6-tagged proteins were purified using nickel columns (Qiagen)cells, L. D. and Z. J. C., unpublished data). Thus, acti-
according to Manufacturer’s instruction.
vated IKK appears to be capable of activating another
IKK to amplify the signals, raising the possibility that
the activation loop of IKK is needed to maintain full Cell Culture, Transfection, and Reporter Gene Assays
70Z and 1.3E2 (NEMO-deficient) cells were kindly provided by Dr.activity of IKK. Consistent with this possibility, we found
Carol Sibley (University of Washington). These cells were culturedthat a recombinant IKKb mutant lacking MAPK phos-
in RPMI1640 supplemented with 10% fetal calf serum (FCS). Humanphorylation sites in the activation loop (S177A/S181A)
embryonic kidney 293 cells were cultured in DMEM plus 10% FCS.retains significant IkB kinase activity (Z. J. C., unpub-
Transfection of 293 cells was carried out according to the calciumlished data). All of these data can be reconciled in a
phosphate precipitation method as previously described (Spencer
model whereby full activation of IKK involves two steps, et al., 1999). Dual luciferase assays were carried out using a kit
an initiation step through TRAF6-mediated ubiquitina- obtained from Promega. A Renilla luciferase gene driven by the
tion, and an amplification step through autoactivation constitutive CMV promoter was included in all transfection experi-
of IKK as a result of phosphorylation at the activation ments as an internal control to correct for transfection efficiency.
loop. It is possible that in some signaling pathways, an
upstream kinase may directly phosphorylate and acti-
In Vitro Assay for IKK Activationvate IKK, thus bypassing the requirement for ubiquitina-
To detect endogenous IKK activation, cell extracts (5 mg/ml) weretion. However, at least in the TRAF6 pathway, our data
incubated with TRAF6 (or, T6RZC, 0.1 mM) together with an ATP-
show that ubiquitination by TRAF6 plays a key role in regenerating buffer (Chen et al., 1995). After incubation at 308C for
triggering the initial activation step. How TRAF6 and 1 hr, the reaction was analyzed by immunoblotting with a phospho-
other TRAF proteins are activated is presently unknown, IkBa-specific antibody. To identify intermediary factors involved in
but it may involve receptor-mediated dimerization or TRAF6-mediated IKK activation, we used a reconstitution assay by
adding 35S-IkBa (0.5 ml) and purified IKK complex (5 nM) to a 5 mloligomerization of these proteins through the conserved
reaction mixture that also contains ATP (2 mM), TRAF6 (0.1 mM),C-terminal TRAF domains (Baud et al., 1999).
and column fractions (0.5–1 ml). In most IKK activation assays, E1The enzymatic pathways for the synthesis of K63-
(0.1 mM) and Ub (0.1 mM) were also added to enhance the reaction,linked polyUb chains are conserved from yeast to man.
although they can be supplied from the wheat germ extracts usedHomologs of Ubc13 and Uev1A are present in yeast,
for in vitro translation of IkBa. As an assay for purification of TRIKA1,
and homologs of Ubc13, Uev1A, and TRAF6 can also be reaction mixtures also contain 0.5 mg TRIKA2/FrIIa, a fraction eluted
found in Drosophila, which possesses highly conserved from Q-Sepharose with 0.2 M NaCl. The reaction was carried out at
dorsoventral patterning and immunity pathways that re- 308C for 1 hr, and then analyzed using a PhosphorImager (Molecular
semble those of NF-kB/IkB in vertebrates. Perhaps the Dynamics) following SDS-PAGE.
formation of K63-linked polyUb chains is an evolution-
arily conserved defense mechanism for an organism to
Purification of TRIKA1 from HeLa Cytosolic Extractsprotect against stressful insults ranging from heat and
and Peptide Mass FingerprintingUV damage to pathogens (innate immunity).
All procedures were carried out at 48C. HeLa cells from 50 liters of
suspension culture were resuspended in 70 ml of hypotonic buffer
Experimental Procedures (10 mM Tris-HCl [pH 7.5], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT,
and 0.5 mM PMSF), and then lysed in a Dounce homogenizer. Cell
Materials debris was removed by ultracentrifugation at 100,000 3 g for 1
HeLa S3 cells were purchased from the Cell Culture Center (Minne- hr. The cleared supernatant (S100) was applied to a Q-sepharose
apolis). The antibodies against IkBa (C21), Myc (9E10), and Ub column (60 ml bed volume) preequilibrated with Buffer B (20 mM
(P4D1) were purchased from Santa Cruz Biotech. Phospho-IkBa- Tris-HCl [pH 7.5], 0.5 mM DTT, 0.5 mM PMSF, 1 mg/ml leupeptin, and
specific antibody was obtained from New England Biolabs. Anti- 0.1 M NaCl). The flow-through (containing TRIKA1) was subjected to
FLAG antibodies were purchased through Sigma. MG132, lactacys- ammonium sulfate precipitation (40%–80%), followed by dialysis
tin, and staurosporin were from Calbiochem. against Buffer C (50 mM HEPES-OH [pH 6.5], 0.5 mM PMSF, and
0.5 mM DTT) overnight. The dialyzed proteins were loaded onto
an SP cation exchange column (5 ml bed volume) using a FastPlasmids and Proteins
Ub and various Ub mutants were expressed in a modified E. coli Performance Liquid Chromatography (FPLC, Pharmacia) system.
Bound proteins were eluted with a 100 ml linear gradient of NaClstrain, BL21(DE3)pJY2, to prevent misincorporation of lysines (You
et al., 1999). E1 was purified from calf thymus by covalent affinity (0–250 mM). Fractions that contain TRIKA1 activity (90 mM NaCl)
were pooled and concentrated before loading onto a Superdex-75chromatography on Ub-Sepharose. Expression plasmids for GST-
Ubch5c and GST-Ubc13 were kindly provided by Dr. Alan Weissman gel filtration column (24 ml bed volume, Pharmacia), which was
preequilibrated with Buffer D (50 mM Tris-HCl [pH 7.5], 0.5 mM(NCI). IkBa and mutants were in vitro translated in wheat germ
extract in the presence of 35S-methionine (Chen et al., 1995). IKK DTT, 0.5 mM PMSF, and 150 mM NaCl). After elution with Buffer D,
fractions containing the TRIKA1 activity were pooled and loadedcomplex was purified form HeLa cells or from calf thymus using
ATP-Sepharose (Upstate Biotechnology Inc.; Spencer et al., 1999). directly onto a hydroxylapatite column (2 ml bed volume, Bio-Rad)
preequilibrated with Buffer E (20 mM HEPES [pH6.8] and 0.5 mMMEKK1 protein was expressed in baculovirus-infected Sf9 insect
cells and purified as described previously (Lee et al., 1997). cDNAs DTT). The column was eluted with a 20 ml gradient of potassium
phosphate buffer (0–200 mM) at pH 6.8. Fractions that containfor TRAF6 and a truncated form of TRAF6 fused to gyrase B (T6RZC)
were gifts from Dr. Jun Ichiro-Inoue (University of Tokyo). These TRIKA1 activity (80 mM phosphate) were adjusted to pH 8.5 with 1
M Tris base, and then applied to a MonoQ column (1 ml, Pharmacia)cDNA were subcloned into pFast-Bac (Gibco-BRL) for expression
in Sf9 cells as His6-tagged proteins. While both TRAF6 and T6RZC preequilibrated with Buffer F (20 mM Tris-HCl [pH 8.5], 0.5 mM DTT,
0.5 mM PMSF, and 0.02% Chaps) plus 50 mM NaCl. The columnwork indistinguishably in IKK activation in vitro, T6RZC consistently
gave better expression and was used in place of TRAF6 in most was eluted with a 20 ml gradient of NaCl (50–300 mM) in Buffer F.
The fractions corresponding to the peak of TRIKA1 activity containexperiments. Site-directed mutagenesis of the RING finger of TRAF6
at Cys-70 (C70A) and Cys-85/His-87 (C85A/H87A) was carried out predominantly two proteins with molecular weights of z16 kDa and
19 kDa as judged by silver staining. These bands were excised forusing the QuikChange kit (Stratagene). NEMO cDNA was cloned
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in-gel digest with trypsin. Peptide masses were acquired by matrix- Baud, V., Liu, Z.-G., Bennett, B., Suzuki, N., Xia, Y., and Karin, M.
(1999). Signaling by proinflammatory cytokines: oligomerization ofassisted laser desorption/ionization (MALDI) mass spectrometry us-
ing a Voyager DE time-of-flight (TOF) spectrometer (PE Biosystems). TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target
gene induction via an amino-terminal effector domain. Genes Dev.
13, 1297–1308.Cloning and Expression of Ubc13 and Uev1A, and Generation
of Antisera Brockman, J.A., Scherer, D.C., McKinsey, T.A., Hall, S.M., Qi, X.,
Ubc13 and UEV1A were cloned from human placenta cDNA library Lee, W.Y., and Ballard, D.W. (1995). Coupling of a signal response
(Clontech) by PCR with primers designed according to published domain in IkBa to multiple pathways for NF-kB activation. Mol. Cell.
sequences (Ubc13: D83004; Uev1A/CROC-1A: U39360). The PCR Biol. 15, 2809–2818.
fragments were cloned into the NdeI and BamH1 sites of pET14b Brown, K., Gerstberger, S., Carlson, L., Franzoso, G., and Siebenlist,
(Novagen) in frame with the N-terminal His6 tag for expression in E. U. (1995). Control of Ik B-alpha proteolysis by site-specific, signal-
coli. While the sequence of Ubc13 was in complete agreement with induced phosphorylation. Science 267, 1485–1488.
the published sequence, the sequence of Uev1A differed from the
Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D.V.published sequence (U39360) in two nucleotides (deletion of a G at
(1996). TRAF6 is a signal transducer for interleukin-1. Nature 383,position 93 and insertion of a C at position 116), which results in a
443–446.replacement of 6 amino acids (SKSPSQ to VKVPRN; residues 32–37
Chau, V., Tobias, J.W., Bachmair, A., Marriott, D., Ecker, D.J., Gonda,in Figure 3E). This difference was unlikely due to PCR or cloning
D.K., and Varshavsky, A. (1989). A multiubiquitin chain is confinedmutation because we found more than 30 independent EST se-
to specific lysine in a targeted short-lived protein. Science 243,quences that matched exactly with our sequence. Human Mms2
1576–1583.also contains this VKVPRN sequence at the N terminus, and we
found that Mms2 functioned indistinguishably from Uev1A in IKK Chen, Z.J., and Maniatis, T. (1998). Role of the ubiquitin-proteasome
activation (data not shown). pathway in NF-kB activation. In Ubiquitin and the Biology of the
Site-directed mutagenesis of Ubc13 at Cys-87 (C87A) was carried Cell, J.-M. Peters, J.R. Harris, and D. Finley, eds. (New York: Plenum
out using the QuickChange kit (Stratagene). Both the wild-type and Press), pp.303–322.
mutant Ubc13 were subcloned into pEF-IRES-P for expression in Chen, Z.J., Hagler, J., Palombella, V.J., Melandri, F., Scherer, D.,
mammalian cells under the control of the strong EF1a promoter. Ballard, D., and Maniatis, T. (1995). Signal-induced site-specific
For expression of recombinant Ubc13 and Uev1A, pET14b-Ubc13 phosphorylation targets IkBa to the ubiquitin-proteasome pathway.
and pET14b-Uev1A were transformed into BL21(DE3)pLys (Nova- Genes Dev. 9, 1586–1597.
gen), respectively. Following induction with IPTG, cell extracts were
Chen, Z.J., Parent, L., and Maniatis, T. (1996). Site-specific phos-
loaded onto an Ni-NTA column (1 ml, Qiagen) to purify the His6- phorylation of IkBa by a novel ubiquitination-dependent protein ki-
tagged proteins. For antibody production, 2 mg of purified His6- nase activity. Cell 84, 853–862.
Ubc13 and His6-Uev1A were used to immunize rabbits in the facility
Courtois, G., Whiteside, S.T., Sibley, C.H., and Israel, A. (1997). Char-of Rockland, Inc. (Gilbertsville, PA).
acterization of a mutant cell line that does not activate NF-kB in
response to multiple stimuli. Mol. Cell. Biol. 17, 1441–1449.Depletion of Endogenous Uev1A with GST-Ubc13-Sepharose
Ghosh, S., May, M.J., and Kopp, E.B. (1998). NF-kB and Rel proteins:One hundred microliters of 293 cell extracts (9 mg/ml) was mixed
evolutionarily conserved mediators of immune responses. Annu.with 20 ml of glutathione-Sepharose beads preloaded with 80 mg of
Rev. Immunol. 16, 225–260.GST-Ubc13 or the same amount of GST (control). After mixing end-
to-end at 48C for 1 hr, the beads were removed by centrifugation Hicke, L. (1999). Gettin’ down with ubiquitin: turning off cell-surface
and the supernatant was mixed with another 20 ml of GST-Ubc13 receptors, transporters and channels. Trends. Cell Biol. 9, 107–112.
or GST beads as described above. The supernatant from the second Hofmann, R.M., and Pickart, C.M. (1999). Noncanonical MMS2-
precipitation was collected for IKK activation assay. encoded ubiquitin-conjugating enzyme functions in assembly of
novel polyubiquitin chains for DNA repair. Cell 96, 645–653.
Ubiquitination Assay
Israel, A. (2000). The IKK complex: an integrator of all signals that
For the synthesis of polyUb chains, the reaction mixture contained
activate NF-kB? Trends. Cell Biol. 10, 129–133.
E1 (0.1 mM), Ubc13/Uev1A (0.4 mM), TRAF6 (0.1 mM), Ub (0.1 mM),
Laney, J.D., and Hochstrasser, M. (1999). Substrate targeting in theand an ATP-regenerating system (see above). The reaction was
ubiquitin system. Cell 97, 427–430.carried out at 308C for 1 hr and then resolved by SDS-PAGE. Ubiquiti-
Lee, F.S., Hagler, J., Chen, Z., and Maniatis, T. (1997). Activation ofnated products were detected by immunoblotting with a Ub-specific
the IkBa kinase complex by MEKK1, a kinase of the JNK pathway.antibody (P4D1).
Cell 88, 213–222.
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